Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.43 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | XBP1 | P17861 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | ADH1B | P00325 | 3/20 | 0.41 |
| ▸ | ADH1C | P00326 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL667726 | 0.93 | RELA (0.43) | ALDH1A1MAPTLMNAMAPK1ADH1B | |
| SCHEMBL966697 | 0.91 | FAAH (0.46) | ALDH1A1MAPTLMNAMAPK1ADH1B | |
| SCHEMBL4910687 | 0.91 | FAAH (0.46) | ALDH1A1MAPTLMNAMAPK1ADH1B | |
| SCHEMBL8637402 | 0.91 | FAAH (0.46) | ALDH1A1MAPTLMNAMAPK1ADH1B | |
| SCHEMBL7522857 | 0.91 | FAAH (0.46) | ALDH1A1MAPTLMNAMAPK1ADH1B | |
| SCHEMBL1751775 | 0.91 | FAAH (0.46) | ALDH1A1MAPTLMNAMAPK1ADH1B | |
| SCHEMBL423937 | 0.85 | — | — | |
| SCHEMBL8520694 | 0.82 | RELA (0.37) | HPGDALDH1A1MAPTLMNAMAPK1 | |
| SCHEMBL7614571 | 0.81 | HPGD (0.43) | HPGDALDH1A1MAPTLMNANPC1 | |
| SCHEMBL1387740 | 0.79 | ALDH1A1 (0.41) | HPGDALDH1A1MAPTLMNANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4410522-A | BACTERICIDES | TOYAMA CHEMICAL CO., LTD. (JP) | 1983-10-18 | — | — | US | claimed |
| US-11365192-B2 | Pyridine compound substituted with azole | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2022-06-21 | — | — | US | disclosed |
| US-20210122741-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2021-04-29 | — | — | US | disclosed |
| EP-3666766-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | Taisho Pharmaceutical Co., Ltd. (JP) | 2020-06-17 | — | — | EP | disclosed |
| CN-110914254-A | Azole-substituted pyridine compound | 大正制药株式会社 | 2020-03-24 | — | — | CN | disclosed |
| US-9066977-B2 | Method of utilization of combination of benzophenone derivative or salt thereof and immunosuppressing agent, and pharmaceutical composition comprising these components | TOYAMA CHEMICAL CO., LTD. (JP) | 2015-06-30 | — | — | US | disclosed |
| US-9012482-B2 | Drug containing benzophenone derivative or its salt | TOYAMA CHEMICAL CO., LTD. (JP) | 2015-04-21 | — | — | US | disclosed |
| EP-2258361-B1 | USE OF BENZOPHENONE DERIVATIVE OR SALT THEREOF AND TNFalpha INHIBITOR IN COMBINATION AND PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVE OR SALT THEREOF AND THE INHIBITOR | TOYAMA CHEMICAL CO LTD (JP) | 2014-09-17 | — | — | EP | disclosed |
| US-8835461-B2 | Substituted 3-hydroxy-4-pyridone derivative | SHIONOGI & CO., LTD. (JP) | 2014-09-16 | — | — | US | disclosed |
| EP-2266557-B1 | COMBINATION OF BENZOPHENONE DERIVATIVE OR SALT THEREOF AND IMMUNOSUPPRESSING AGENT, AND PHARMACEUTICAL COMPOSITION COMPRISING THESE COMPONENTS | TOYAMA CHEMICAL CO LTD (JP) | 2013-08-14 | — | — | EP | disclosed |
| EP-0367130-A2 | Pyrrolidine derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-05-09 | — | — | EP | disclosed |
| US-4916152-A | THROMBOXANE A2 ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-04-10 | — | — | US | disclosed |
| EP-0289911-A2 | Pyrrolidine derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1988-11-09 | — | — | EP | disclosed |
| US-4410522-A | BACTERICIDES | TOYAMA CHEMICAL CO., LTD. (JP) | 1983-10-18 | — | — | US | disclosed |
| US-4379152-A | Cephalosporins | TOYAMA CHEMICAL CO., LTD. (JP) | 1983-04-05 | — | — | US | disclosed |
| US-4327097-A | BACTERICIDES FOR MAMMALS | TOYAMA CHEMICAL CO., LTD. (JP) | 1982-04-27 | — | — | US | disclosed |
| US-4219554-A | Novel penicillins and cephalosporins and process for producing same | TOYAMA CHEMICAL COMPANY, LIMITED (JP) | 1980-08-26 | — | — | US | disclosed |
| US-4112090-A | BACTERICIDE | TOYAMA CHEMICAL CO., LTD. (JP) | 1978-09-05 | — | — | US | disclosed |
| US-4110327-A | BACTERICIDES | TOYAMA CHEMICAL CO., LTD. (JP) | 1978-08-29 | — | — | US | disclosed |
| US-4087424-A | Novel penicillins and cephalosporins and process for producing the same | TOYAMA CHEMICAL CO., LTD. (JA) | 1978-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210122741-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | CYP2C19, CYP4A11, CYP11B1 | HPGD 66/4885ALDH1A1 378/4885MAPT 4621/4885 |
| US-11365192-B2 | Pyridine compound substituted with azole | CYP2C19, CYP4A11, CYP11B1 | HPGD 66/4885ALDH1A1 378/4885MAPT 4621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.